On Sept. 21, 2017, MilliporeSigma, the life-science subsidiary of Merck KGaA, announced the opening of its first end-to-end biodevelopment center in the Asia Pacific (APAC) region. The center, located in Shanghai, China, will provide a range of process development capabilities and services, inclOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.